Fig. 3
Assessment of druggability and in vivo replicability of YIAD002 in APP/PS1 mice. A Effective permeability coefficient (Pe, 10−6 cm/s) of YIAD002 was estimated using BBB-PAMPA. B CYP inhibition profile. C Stability of YIAD002 in liver microsomes of human, rat, and mouse. D Stability of YIAD002 in human and rat plasma. E Scheme for APP/PS1 administration. YIAD002 (10 mg/kg/day, n = 8, and 30 mg/kg/day, n = 8) was orally administered to 7.5-month-old male APP/PS1 mice for 10 weeks. F Escape latency during Morris water maze. G Latency to target and H target crossings. I Representative traces of probe trial. J Images of 6E10-immunostained brains (scale bars: 400 μM). Plaque number and area of the whole brain (K), cortex (L), and hippocampus (M) of the mice were quantified. All statistical comparisons were made with the vehicle-treated APP/PS1 mouse group (TG (0 mpk)). One-way analysis of variance followed by Bonferroni’s post hoc comparisons tests were performed in all statistical analyses (*P < 0.05, **P < 0.01, ****P < 0.0001). Data are presented as mean ± SEM